Gelişiyor
Sağlık·13.06.2026AI özeti
New Alzheimer's Drug Donanemab Launched in India Amidst Cost and Efficacy Debates
Eli Lilly's new Alzheimer's drug, donanemab (Lormalzi), has been approved in India to slow disease progression by clearing brain plaques. While offering potential benefits, experts express concerns about its high cost, the need for early diagnosis, and the extent of its real-world impact in India.
E
Economic Times3 dk okuma